Houston based ThromboVision, Inc. has won the first annual Michael E. DeBakey Life Science Award, which carries a $50,000 cash prize to assist in propelling the company's technology toward commercial success.
ThromboVision's initial product, currently in late-stage development, is a platelet function monitor called the ThromboGuide (T-Guide). This device will help physicians individualize antiplatelet therapy when they treat cardiovascular patients for heart attacks, strokes and stent occlusions.
The award was presented to ThromboVision's president and CEO, Edward R. Teitel, M.D., JD, MBA, by Dr. DeBakey; Malcolm Gillis, PhD, BioHouston chairman; and John Mendelsohn, M.D., president, The University of Texas M.D. Anderson Cancer Center, at BioHouston's 2006 Texas Life Science Conference.
"We're in this business to save lives," said Dr. Teitel. "The sooner we can submit our system to the FDA for approval to market, the sooner we can help physicians improve their patients' care. We expect that access to the HTC's high-level planning expertise and potential funding sources will accelerate our growth model."
For more information visit www.thrombovision.com